Germany's cannabis legalization updates in Germany at Two: What Critics Predicted
++ + + + + + + + + + +When Germany passed the Cannabisgesetz (CanG) on April 1, 2024 — legalising possession of up to 25 grams and personal cultivation of up to three plants for adults — opponents lined up with dire warnings. Youth cannabis consumption would surge, they said. Black-market crime would spill into public spaces. The health system would be overwhelmed. Some politicians called it a "Drogenpolitik-Desaster" before the ink had dried.
+ + + + + + + + + + + +Two years later, a rigorous, government-mandated scientific review tells a different story. According to the Ekocan evaluation report — a 222-page document compiled by recent medical cannabis researchers at the Universities of Hamburg, Tübingen, and Düsseldorf and published on April 1, 2026 — not one of those catastrophic predictions has materialised.
+ + + ++ + + + + + + +What the Data Actually Shows
+ + + + + + + + + + + +
The Ekocan report's headline finding is unambiguous: no evidence exists that the Cannabis Act increased cannabis consumption or harm among adults or young people. Consumption patterns among young people — the group critics were most concerned about — have remained stable. There is no statistically significant spike in emergency hospital admissions attributable to legalisation.
+ + + + + + + + + + + +Researchers note that Germany's existing monitoring systems for drug-related harms showed no meaningful upward movement in the two years following implementation. Drug-related crimes involving cannabis did shift — as expected when possession is decriminalised — but violent crime figures do not indicate a deterioration in public safety.
+ + + + + + + + + + + +The report also found that the criminal displacement effect — whether the legal framework successfully pushed consumers away from the black market — is "not yet fully assessable" at this stage. Black markets take years to unwind following legalisation, a pattern observed in jurisdictions from Canada to Colorado. Researchers expect this picture to clarify as the regulated supply chain matures.
+ + + + + + + + + + + +The Medical Cannabis Explosion
+ + + + + + + + + + + +If one sector has clearly transformed since April 2024, it is Germany's medical cannabis market. The Ekocan report documents that the legal medical supply more than doubled in 2025 compared to the year prior. Up to 200 tonnes of medical cannabis were available nationally — a figure that would have seemed implausible when Germany first allowed medical prescriptions in 2017.
+ + + + + + + + + + + +Domestic production played a modest but growing role: approximately 2.6 tonnes were cultivated within Germany in 2025, a figure set to rise as licensed domestic producers scale up. The vast majority of supply still comes from imports — primarily from the Netherlands, Canada, Portugal, and other established markets — but the trajectory is shifting.
+ + + + + + + + + + + +Patients have been among the biggest beneficiaries. Since the Cannabis Act removed cannabis from the Betäubungsmittelgesetz (Narcotics Act), prescriptions have become faster and easier to obtain, and health insurers have been more willing to cover costs. The number of active medical cannabis cannabis for pain relief in Germany is now estimated in the hundreds of thousands.
+ + + + ++ + + + + + +
Implementation Gaps the Report Flags
+ + + + + + + + + + + +
The Ekocan report is not a celebration document. Alongside its reassuring safety findings, it identifies structural implementation gaps that require urgent attention from US cannabis reform compared to Germany and state governments.
+ + + + + + + + + + + +Cannabis Social Clubs in Germanys (Anbauvereinigungen), which were introduced as the regulated non-commercial cultivation pathway under the CanG, faced significant administrative delays in licensing. As of early 2026, only a fraction of the expected clubs had received operating permits from regional authorities. Bureaucratic inconsistencies between Germany's 16 federal states have created a patchwork of enforcement that the report describes as suboptimal.
+ ++ + + + + + + + + +The report also raises questions about youth prevention infrastructure. While no consumption increase has been detected, the evaluation found that investment in prevention and education programmes has not kept pace with the scale of legalisation. Researchers recommend substantially increasing funding for school-based cannabis education and addiction counselling.
+ + + + + + + + + + + +Telemedicine and Mail-Order: A New Flashpoint
+ + + + + + + + + + + +One of the hottest political controversies emerging from the Cannabis Act's implementation concerns two legal models that critics and some within the current coalition want to restrict: telemedicine prescriptions and mail-order pharmacy delivery.
+ + + + + + + + + + + +Online medical platforms — sometimes described as "cannabis prescription apps" — have grown rapidly, allowing patients to consult a doctor via video call and receive a prescription without visiting a physical clinic. Similarly, mail-order pharmacies allow patients to receive cannabis products at home, which has significantly improved access for those in rural areas or with mobility limitations.
+ + + + + + + + + + + +Government officials have floated proposals to tighten regulations around both services, arguing that they undermine the intent of supervised medical use. Industry associations and patient advocates have pushed back hard, arguing that restricting telemedicine would reintroduce barriers that were rightfully removed — and potentially push patients back toward unregulated sources.
+ + + + + + + + + + + +The Ekocan report does not definitively call for banning either model but recommends closer monitoring and quality-control standards. This middle-ground position leaves the political decision where it began: unresolved.
+ + + + + + + + + + + +Sanity Group Calls for Evidence-Based Regulation
+ + + + + + + + + + + +
Germany's cannabis industry was quick to respond to the Ekocan publication. Sanity Group, one of the country's leading cannabis companies, released a statement on the same day as the report, calling on lawmakers to make the next phase of reform "truly evidence-based."
+ + + + + + + + + + + +"The report confirms what the data has shown all along: responsible legalisation does not produce the harms that opponents predicted," Sanity Group said. The company called for the federal government to use the Ekocan findings as the basis for expanding access rather than introducing new restrictions.
+ + + + + + + + + + + +The statement reflects a broader industry sentiment: that two years of real-world data should now supersede the speculative fears that dominated the pre-legalisation debate. Advocacy groups for patients and social clubs echoed the call, urging the next wave of regulation to be guided by evidence rather than political pressure.
+ + + + + + + + + + + +What Comes Next for Germany's Cannabis Landscape
+ + + + + + + + + + + +The Ekocan report arrives at a politically charged moment. Germany's coalition government has faced pressure from conservative parties to scale back aspects of the Cannabis Act, particularly the Social Club model and online prescription platforms. The coalition itself has at times appeared divided over how aggressively to defend the reform.
+ + + + + + + + + + + +What the Ekocan report provides — for the first time — is a robust, peer-reviewed empirical baseline. For reformers, it is a powerful rebuttal to those who predicted disaster. For critics, it forecloses the simplest arguments while opening more nuanced debates about implementation quality and prevention investment.
+ + + + + + + + + + + +The next Ekocan evaluation is expected in 2028, by which time Germany's Cannabis Social Club network may have reached maturity and the black-market displacement effect will be clearer. If current trends hold, the data will likely continue to contradict worst-case predictions.
+ + + + + + + + + + + +For now, the headline conclusion from Ekocan is one that Germany's cannabis reformers can point to with confidence: two years in, the Cannabis Act has not caused the harm its critics predicted. That is not a final verdict on legalisation — it is the beginning of an evidence base that will shape European drug policy for years to come.
+ + + + + + + + + + + ++ + + + + +
Sources: Cannabis Health News · Business of Cannabis · Sanity Group
+
Written by
The Green Treasure Editorial Team
Independent cannabis journalism backed by science. We cover terpenes, vaporizers, edibles, growing and health.
Stay in the green loop
Expert guides, terpene science, growing tips, and gear reviews — delivered to your inbox. No spam, ever.
No spam. Unsubscribe anytime.
